RAD50 and neoplasm: When patients were grouped into early tumor stage (T1–2) and low-grade (G1–2) subgroups, low expression of RAD50 was associated with decreased DFS (p = 0.001) (Figure 2E), indicating that RAD50 may be a useful prognostic biomarker for early tumor stage and low-grade subgroups.